Cargando…

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease

BACKGROUND: Diabetic patients present with an accelerated atherosclerotic process and an increased risk for future cardiovascular events. In addition to the risk imposed by the disease itself, pharmacological treatment adds also a sizable risk, especially if certain classes of antidiabetic drugs are...

Descripción completa

Detalles Bibliográficos
Autores principales: Klempfner, Robert, Leor, Jonathan, Tenenbaum, Alexander, Fisman, Enrique Z, Goldenberg, Ilan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403890/
https://www.ncbi.nlm.nih.gov/pubmed/22672501
http://dx.doi.org/10.1186/1475-2840-11-60
_version_ 1782238938549714944
author Klempfner, Robert
Leor, Jonathan
Tenenbaum, Alexander
Fisman, Enrique Z
Goldenberg, Ilan
author_facet Klempfner, Robert
Leor, Jonathan
Tenenbaum, Alexander
Fisman, Enrique Z
Goldenberg, Ilan
author_sort Klempfner, Robert
collection PubMed
description BACKGROUND: Diabetic patients present with an accelerated atherosclerotic process and an increased risk for future cardiovascular events. In addition to the risk imposed by the disease itself, pharmacological treatment adds also a sizable risk, especially if certain classes of antidiabetic drugs are employed. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors have anti-atherosclerotic effects, yet clinical data are scarcely available. DESIGN: We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes. The selected markers are: interleukin-6, high sensitivity C reactive protein, interleukin 1-beta, total adiponectin levels, matrix metallo-proteinase 9 and platelet reactivity testing. Sixty eligible patients will be randomized in a 2:1 ratio to vildagliptin/metformin or metformin only treatment, for a 3-month duration treatment. Blood sampling for the proposed investigations will be taken at enrollment and immediately after completion of the study period. DISCUSSION: Demonstrating antiatherothrombotic properties of dipeptidyl peptidase-4 inhibitors on proven markers is of substantial clinical significance. Coupled with their proven good safety profile these findings could translate into a significant clinical benefit.
format Online
Article
Text
id pubmed-3403890
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34038902012-07-25 Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease Klempfner, Robert Leor, Jonathan Tenenbaum, Alexander Fisman, Enrique Z Goldenberg, Ilan Cardiovasc Diabetol Study Protocol BACKGROUND: Diabetic patients present with an accelerated atherosclerotic process and an increased risk for future cardiovascular events. In addition to the risk imposed by the disease itself, pharmacological treatment adds also a sizable risk, especially if certain classes of antidiabetic drugs are employed. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors have anti-atherosclerotic effects, yet clinical data are scarcely available. DESIGN: We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes. The selected markers are: interleukin-6, high sensitivity C reactive protein, interleukin 1-beta, total adiponectin levels, matrix metallo-proteinase 9 and platelet reactivity testing. Sixty eligible patients will be randomized in a 2:1 ratio to vildagliptin/metformin or metformin only treatment, for a 3-month duration treatment. Blood sampling for the proposed investigations will be taken at enrollment and immediately after completion of the study period. DISCUSSION: Demonstrating antiatherothrombotic properties of dipeptidyl peptidase-4 inhibitors on proven markers is of substantial clinical significance. Coupled with their proven good safety profile these findings could translate into a significant clinical benefit. BioMed Central 2012-06-06 /pmc/articles/PMC3403890/ /pubmed/22672501 http://dx.doi.org/10.1186/1475-2840-11-60 Text en Copyright ©2012 Klempfner et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Klempfner, Robert
Leor, Jonathan
Tenenbaum, Alexander
Fisman, Enrique Z
Goldenberg, Ilan
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
title Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
title_full Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
title_fullStr Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
title_full_unstemmed Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
title_short Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
title_sort effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403890/
https://www.ncbi.nlm.nih.gov/pubmed/22672501
http://dx.doi.org/10.1186/1475-2840-11-60
work_keys_str_mv AT klempfnerrobert effectsofavildagliptinmetformincombinationonmarkersofatherosclerosisthrombosisandinflammationindiabeticpatientswithcoronaryarterydisease
AT leorjonathan effectsofavildagliptinmetformincombinationonmarkersofatherosclerosisthrombosisandinflammationindiabeticpatientswithcoronaryarterydisease
AT tenenbaumalexander effectsofavildagliptinmetformincombinationonmarkersofatherosclerosisthrombosisandinflammationindiabeticpatientswithcoronaryarterydisease
AT fismanenriquez effectsofavildagliptinmetformincombinationonmarkersofatherosclerosisthrombosisandinflammationindiabeticpatientswithcoronaryarterydisease
AT goldenbergilan effectsofavildagliptinmetformincombinationonmarkersofatherosclerosisthrombosisandinflammationindiabeticpatientswithcoronaryarterydisease